LONDON and MINNEAPOLIS, Sept. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and Cizzle Biotechnology Holdings plc, the UK-based diagnostics developer, are pleased to announce recent progress evaluating specific monoclonal antibodies for Cizzle's CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of using the Simple Western platform from ProteinSimple (a Bio-Techne Brand) for high throughput detection of the CIZ1B cancer biomarker which may be useful in the detection of early-stage lung cancer.
Read more at prnewswire.comCizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western™ Platform
PR Newswire -
Tue Sep 19, 2023
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Tesla%20car%20with%20symbol%20by%20Michael%20Fortsch%20via%20Unsplash.jpg)
/Unitedhealth%20Group%20Inc%20HQ%20photo-by%20jetcityimage%20via%20iStock.jpg)
/Advanced%20Micro%20Devices%20Inc_%20office%20sign-by%20Poetra_RH%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/AI%20technology%20-%20by%20Wanan%20Yossingkum%20via%20iStock.jpg)
/Amazon%20-%20Image%20by%20Tada%20Images%20via%20Shutterstock.jpg)